Health brief
Alzheimer's Blood Tests, Autoimmune Data, and CMS Exclusion Power
FDA clears Roche and Lilly's Alzheimer's blood test while Nektar reports positive Phase 2b eczema data and HHS expands CMS enforcement powers.
Health
FDA clearance of Roche and Lilly's Alzheimer's blood test replaces expensive PET scans — opening up routine screening in primary care offices.
BackgroundDiagnosing Alzheimer's disease historically required expensive PET brain scans or invasive lumbar punctures that restricted testing to specialized clinics. Single-biomarker blood tests allow primary care physicians to screen patients exhibiting early cognitive decline symptoms in routine office visits.
- The Elecsys pTau217 test is the first single-biomarker blood assay cleared to both rule in and rule out amyloid pathology, improving diagnostic precision.
- Labcorp will deploy the test across its nationwide network of standardized clinical laboratory instruments, establishing immediate broad primary care accessibility.
- Broad primary care screening accelerates patient qualification for newly approved disease-modifying antibody treatments before advanced cognitive decline occurs.
Health
Health
Nektar's published Phase 2b results validate regulatory T-cell expansion — unlocking a novel mechanism for chronic autoimmune treatment.
BackgroundAtopic dermatitis is a chronic inflammatory skin condition driven by immune system dysfunction and T-cell imbalance. Regulatory T-cell expansion therapies restore immune tolerance without causing the broad systemic immunosuppression associated with traditional biologics.
- The highest biweekly dose achieved a 61% mean reduction in eczema severity compared to 31% for placebo, satisfying key regulatory benchmarks.
- The 393-patient Phase 2b trial met all primary endpoints, validating regulatory T-cell expansion as a viable therapeutic mechanism.
- Topline Phase 3 results from the ongoing ZENITH AD clinical program are expected next year, setting up potential regulatory submission timelines.
Health
Patient advocates are pushing HHS to lift anti-kickback rules — allowing trial sponsors to pay travel costs for low-income patients.
BackgroundFederal Anti-Kickback Statute regulations restrict trial sponsors from reimbursing patient travel and lodging costs due to patient inducement concerns. Low-income patients face significant financial hurdles traveling to distant clinical sites, limiting trial diversity.
- ACS CAN led 128 health advocacy organizations in submitting a joint petition to the HHS Office of Inspector General, demanding urgent regulatory updates.
- National health data reveals 38% of Americans live over 50 miles from clinical trial centers, creating severe travel expense hurdles for rural populations.
- Proposed safe harbor rules would permit trial sponsors to cover patient travel, lodging, and childcare expenses legally without triggering federal penalty risks.
Health
Health
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
